Top

Published in:

01-11-2018 | Clinical Study

One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Authors: Dieter Henrik Heiland, Gerrit Haaker, Ralf Watzlawick, Daniel Delev, Waseem Masalha, Pamela Franco, Marcia Machein, Ori Staszewski, Oliver Oelhke, Nils Henrik Nicolay, Oliver Schnell

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Introduction

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with peak incidence in patients older than 65 years. These patients are mostly underrepresented in clinical trials and often undertreated due to concomitant diseases. Recently, different therapeutic approaches for elderly patients with GBM were discussed. To date, there is no defined standard treatment. The aim of the present study is to evaluate the functional and oncological outcome in surgical treatment of elderly patients.

Materials and methods

A total of 342 elderly patients aged ≥ 65 years were retrospectively analyzed in our neurosurgical center. Surgical therapy, adjuvant treatment, overall survival (OS) and functional outcome using Karnofsky performance scale (KPS) and Neurological assessment of neuro-oncology-score were analyzed.

Results

The median age at GBM diagnosis was 73.4 (IQR 9.28) years. Median overall survival was 7.5 (CI 95% 6.0–9.1) months and median preoperative or postoperative KPS was 80 (IQR 20). Surgical resection was performed in 216 (63.2%) patients, in 125 patients (36.5%) patients a stereotactic biopsy was performed. The median OS was significantly higher in patients with gross total resection (GTR) compared to partial resection and biopsy (10.8 months; CI 95% 9.5–12.3). Patients with combined radio- and chemo-therapy (RCT) showed significant longer OS, particularly MGMT-negative GBM. Higher preoperative KPS was found to be associated with improved overall survival.

Conclusion

GTR and adjuvant combined RCT provides benefits for overall survival in elderly patients. Therapy decision should be made in regard to preoperative functional status instead of biological age.

Available only for authorised users

Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV (2017) Management of glioblastoma in elderly patients. J Neurol Sci 380:250–255CrossRefPubMed

Stupp R, Dietrich P-Y, Kraljevic SO et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382CrossRefPubMed

Khurana V, Jain S, Smee R, Cook R, Dobes M, Shadbolt B, Smith S, Dexter M (2011) Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surg Neurol Int. https://doi.org/10.4103/2152-7806.90696 CrossRefPubMedPubMedCentral

Morgan ER, Norman A, Laing K, Seal MD (2017) Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study. Curr Oncol. https://doi.org/10.3747/co.24.3424 CrossRefPubMedPubMedCentral

Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neuro-Oncol 91:95–100CrossRef

Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF (2013) Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg 118(4):786–798. https://doi.org/10.3171/2012.10.JNS112268 CrossRefPubMed

Harris G, Jayamanne D, Wheeler H et al (2017) Survival outcomes of elderly patients with glioblastoma multiforme in their 75th year or older treated with adjuvant therapy. Int J Radiat Oncol Biol Phys 98:802–810CrossRefPubMed

Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY (2017) Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: an analysis of the national cancer database. Cancer. https://doi.org/10.1002/cncr.30730 CrossRefPubMed

Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037CrossRefPubMed

10.

Tsang DS, Khan L, Perry JR, Soliman H, Sahgal A, Keith JL, Mainprize TG, Das S, Zhang L, Tsao MN (2015) Survival outcomes in elderly patients with glioblastoma. Clin Oncol. https://doi.org/10.1016/j.clon.2014.11.026 CrossRef

11.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed

12.

Nayak L, Deangelis LM, Brandes AA et al (2017) The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro-Oncology 19:625–635CrossRefPubMedPubMedCentral

13.

Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed

14.

Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMed

15.

Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed

16.

Minniti G, Salvati M, Arcella A, Buttarelli F, D’Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol 102:311–316CrossRef

17.

Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350CrossRefPubMed

18.

Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715CrossRefPubMed

19.

Chaichana KLKK, Chaichana KLKK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A, Quiñones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594CrossRefPubMed

20.

Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quiñones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18(1):239–245. https://doi.org/10.1245/s10434-010-1242-6 CrossRefPubMed

21.

Oszvald Á, Güresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116:357–364CrossRefPubMed

22.

Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-Oncology 17:868–881CrossRefPubMedPubMedCentral

23.

Babu R, Komisarow JM, Agarwal VJ et al (2016) Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. https://doi.org/10.3171/2015.4.JNS142200 CrossRefPubMed

24.

Lorimer CF, Saran F, Chalmers AJ, Brock J (2016) Glioblastoma in the elderly—how do we choose who to treat? J Geriatr Oncol https://doi.org/10.1016/j.jgo.2016.07.005 CrossRefPubMed

25.

Gately L, Collins A, Murphy M, Dowling A (2016) Age alone is not a predictor for survival in glioblastoma. J Neuro-Oncol. https://doi.org/10.1007/s11060-016-2194-x CrossRef

26.

Zanello M, Roux A, Ursu R et al (2017) Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment? On the Behalf of the Club de Neuro-Oncologie of the Société Française de Neurochirurgie. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2573-y CrossRef

Title: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?
Authors: Dieter Henrik Heiland
Gerrit Haaker
Ralf Watzlawick
Daniel Delev
Waseem Masalha
Pamela Franco
Marcia Machein
Ori Staszewski
Oliver Oelhke
Nils Henrik Nicolay
Oliver Schnell
Publication date: 01-11-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2964-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma

Trametinib for progressive pediatric low-grade gliomas

Correction to: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Palliative care education in U.S. adult neuro-oncology fellowship programs

Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma

Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus